(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 April 2023 (20.04.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/064943 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 11/00* (2006.01)

(21) International Application Number:
PCT/US2022/078175

(22) International Filing Date:
14 October 2022 (14.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/255,898	14 October 2021 (14.10.2021)	US
63/359,835	09 July 2022 (09.07.2022)	US
63/359,875	10 July 2022 (10.07.2022)	US

(71) Applicant: **PLIANT THERAPEUTICS, INC.** [US/US]; 260 Littlefield Avenue, South San Francisco, California 94080 (US).

(72) Inventors: **LEFEBVRE, Eric**; c/o Pliant Therapeutics, Inc., 260 Littlefield Avenue, South San Francisco, California 94080 (US). **COSGROVE, Gregory P.**; c/o Pliant Therapeutics, Inc., 260 Littlefield Avenue, South San Francisco, California 94080 (US).

(74) Agent: **CERPA, Robert** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS



(A)



(I)



(II).

(57) Abstract: The invention relates to methods of treating a subject for a disease comprising administration of compounds of Formula (A), Formula (I), or Formula (II): (I)(II) or a salt thereof, wherein R^1, R^2, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, q and p are as described herein; and administering to the subject at least a second drug selected from pirfenidone and nintedanib, or a salt thereof. Compounds of Formula (A), Formula (I), Formula (II), and pharmaceutical compositions thereof are $\alpha v\beta_6$ integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IFF) and nonspecific interstitial pneumonia (NSIP).

WO 2023/064943 A1

[Continued on next page]

Published:
— *with international search report (Art. 21(3))*